China Pharma Holdings (CPHI) Depreciation & Amortization (CF) (2010 - 2026)
China Pharma Holdings' (CPHI) quarterly Depreciation & Amortization (CF) came in at $980570.0 in Q1 2026, up 197.76% YoY from $329313.0 in Q1 2025, and up 97.13% on a QoQ basis from $497425.0 in Q4 2025.
China Pharma Holdings (CPHI) Depreciation & Amortization (CF) (2010 - 2026) Analysis & Trends
China Pharma Holdings (CPHI) has 17 years of Depreciation & Amortization (CF) data on file, last reported at $980570.0 in Q1 2026.
- Quarterly Depreciation & Amortization (CF) rose 197.76% year-over-year to $980570.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.2 million (down 2.65% YoY) and the FY2025 annual result came in at $1.5 million, down 42.57% from the prior year.
- Depreciation & Amortization (CF) climbed to $980570.0 in Q1 2026, from $497425.0 in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $980570.0 in Q1 2026 to a low of $320863.0 in Q2 2025.
- A 5-year average of $620968.1 and a median of $683094.0 in 2023 frame the typical range for Depreciation & Amortization (CF).
- Annual changes were most pronounced in 2025 — Depreciation & Amortization (CF) slumped 56.6% — and 2026, when it surged 197.76%.
- Tracing CPHI's Depreciation & Amortization (CF) over 5 years: stood at $639425.0 in 2022, then gained by 8.82% to $695835.0 in 2023, then sank by 35.61% to $448073.0 in 2024, then climbed by 11.01% to $497425.0 in 2025, then jumped by 97.13% to $980570.0 in 2026.
- The last three Depreciation & Amortization (CF) figures came in at $980570.0 (Q1 2026), $497425.0 (Q4 2025), and $356034.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn | 241.00 Mn |
| 3 | Zoetis | 31.79 Bn | 30.11 Bn | 1.05 Bn | 119.00 Mn |
| 4 | Takeda Pharmaceutical | 28.69 Bn | 22.89 Bn | 5.10 Bn | 1.02 Bn |
| 5 | United Therapeutics | 22.25 Bn | 19.58 Bn | 683.80 Mn | 24.20 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 672.30 Mn |
| 7 | Neurocrine Biosciences | 15.58 Bn | 15.19 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | 171.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | China Pharma Holdings | 42.13 Mn | 41.82 Mn | 83,566.00 | 1.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 980,570.00 |
| Mar 31, 2026 | 980,570.00 |
| Dec 31, 2025 | 497,425.00 |
| Dec 31, 2025 | 497,425.00 |
| Sep 30, 2025 | 356,034.00 |
| Sep 30, 2025 | 356,034.00 |
| Jun 30, 2025 | 320,863.00 |
| Jun 30, 2025 | 320,863.00 |
| Mar 31, 2025 | 329,313.00 |
| Mar 31, 2025 | 329,313.00 |
| Dec 31, 2024 | 448,073.00 |
| Dec 31, 2024 | 448,073.00 |
| Sep 30, 2024 | 696,943.00 |
| Sep 30, 2024 | 696,943.00 |
| Jun 30, 2024 | 739,252.00 |
| Jun 30, 2024 | 739,252.00 |
| Mar 31, 2024 | 733,798.00 |
| Mar 31, 2024 | 733,798.00 |
| Dec 31, 2023 | 695,835.00 |
| Dec 31, 2023 | 695,835.00 |